Skip to main content

Table 1 Patient characteristics at baseline (ITT population, n = 70)

From: A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

 

n (%)

Median age, years (range)

61 (39.5-73.8)

   35–49 years

10 (14.3%)

   50–64 years

36 (51.4%)

   ≥ 65 years

24 (34.3%)

Gender

 

   Men

59 (84.3%)

   Women

11 (15.7%)

Median performance status (KPS)

90

   80%

25 (35.7%)

   90%

12 (17.1%)

   100%

33 (47.1%)

Histology

 

   Squamous cell

31 (44.3%)

   Adenocarcinoma

23 (32.9%)

   Large cell Carcinoma

13 (18.6%)

   Giant cell carcinoma

3 (4.3%)

Staging

 

   IIIA

20 (28.6%)

   IIIB

48 (68.6%)

   IV*

2 (2.9%)

Median delay between diagnosis and study entry, months (range)

1 (0.2-6.4)

  1. *Stage IV: Dubious at inclusion, was confirmed at following evaluations.